Diabetes mellitus acts as context-dependent disease modifier across 10 neurological disorders
Background
The global burden of Diabetes mellitus (DM) and neurological disorders is rapidly escalating, driven by population aging and metabolic syndrome. While DM's role in peripheral neuropathy is established, its broader impact on central and peripheral nervous system diseases remains a critical gap. Current therapies for many neurological syndromes lack disease-modifying capabilities, necessitating a deeper understanding of modifiable risk factors and intersecting pathologies. This review synthesizes evidence on DM's influence across a spectrum of neurological conditions, aiming to identify shared mechanisms and potential therapeutic repurposing strategies.
Study Design
Researchers conducted a narrative review, synthesizing current epidemiological, clinical, genetic, and mechanistic evidence. The review specifically examined the relationship between Diabetes mellitus and 10 clinically important neurological disorders: Alzheimer's disease (AD), vascular dementia (VaD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multiple sclerosis (MS), myasthenia gravis (MG), and neuromyelitis optica spectrum disorder (NMOSD). The primary objective was to characterize DM's role as a context-dependent disease modifier.
Results
The review found that Diabetes mellitus consistently acts as a context-dependent disease modifier across the 10 neurological disorders examined. DM was observed to increase risk in some conditions, while appearing protective or delaying onset in others, and influencing disease phenotype, progression, and treatment response. Key areas of mechanistic convergence identified include insulin resistance, inflammation, disrupted energy homeostasis, and genetic predisposition. Divergences were also noted, shaped by disease-specific pathology. The analysis highlighted diagnostic challenges and opportunities for improved risk stratification at the interface of metabolic and neurological health. > Growing interest exists in repurposing antidiabetic therapies, particularly metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors, for potential neurological benefit across these diverse conditions, suggesting a promising avenue for future research and clinical translation.
Key Findings
- Diabetes mellitus modulates risk, phenotype, and prognosis across 10 distinct neurological disorders.
- DM increases risk in some neurological disorders while appearing protective or delaying onset in others.
- Mechanistic convergences include
insulin resistance,inflammation, anddisrupted energy homeostasis. - Antidiabetic therapies like metformin, GLP-1 receptor agonists, and SGLT2 inhibitors show promise for neurological benefit.
Why It Matters
This comprehensive review underscores the profound and varied impact of Diabetes mellitus on neurological health, moving beyond traditional peripheral neuropathy. Understanding DM's role as a disease modifier is crucial for clinicians and researchers, enabling better risk stratification and potentially informing novel therapeutic strategies. For individuals managing metabolic health, this highlights the broad systemic implications of glycemic control. The identified potential for repurposing existing antidiabetic medications like metformin and GLP-1 receptor agonists for neurological benefits suggests that future protocols might integrate these compounds not just for metabolic control, but also for neuroprotection or disease modification in conditions like AD or PD. This opens doors for exploring new stack combinations and treatment paradigms that address both metabolic and neurological health concurrently.
diabetes
neurological disorders
alzheimer's disease
parkinson's disease
multiple sclerosis
inflammation